Acid Sphingomyelinase Deficiency (ASMD) — Xenpozyme Coverage
Customize your policy alerts
Sign up for Molina Healthcare Policy C24670-A alerts
Get alerted when Policy C24670-A changes without checking for updates manually.
Monitor payer policy activity
Prior authorization coverage of intravenous Xenpozyme (olipudase alfa-rpcp) for adult and pediatric members with acid sphingomyelinase deficiency, limited to non-central nervous system manifestations and subject to diagnostic, clinical, specialist, and dosing documentation requirements.
The review history reports revisions to required medical information, continuation of therapy, duration of approval, contraindications or exclusions, discontinuation, and other special considerations.
The review history reports revisions to available dosage forms and references.
The review history reports revisions to coding and billing information and references.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.